FAK Inhibitors
2 drugsAbout FAK
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase involved in cell adhesion, migration, proliferation, and survival signaling pathways. Its role in these processes has made it a target for drug development, especially in oncology.
FAK's involvement in tumor growth and metastasis supports its therapeutic potential, despite the lack of direct genetic evidence linking it to specific diseases. Targeting FAK may disrupt cancer progression.
Two FDA-approved drugs target FAK: LORBRENA and AVMAPKI FAKZYNJA CO-PACK (COPACKAGED), both small molecules used in oncology. These drugs highlight FAK inhibition as a therapeutic strategy.
Top FAK Drugs
Pfizer and VERASTEM INC are the companies with approved FAK-targeting drugs.
Limited competition suggests an opportunity for new entrants, but high barriers to entry exist.
FAK Drug Modality Landscape
Modalities
Routes of Administration
FAK is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
FAK Clinical Trials 51 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FAK. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 8 | 3 | 6 | 73% |
| Phase 2 | 22 | 3 | 3 | 16 | 50% |
| Phase 3 | 6 | 2 | 0 | 4 | 100% |
| Phase 4 | 6 | 2 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FAK Drug Approval Timeline (2018 - 2025)
The first FAK-targeting drug was approved in 2018, with the most recent in 2025.
Recent approval indicates continued interest, but monitor for market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FAK. A trial counts if an approved drug acting on FAK is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.